Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Zantac name recognition will help overcome late market entry, consultant predicts.

This article was originally published in The Tan Sheet

Executive Summary

OTC ZANTAC NAME RECOGNITION WILL HELP OVERCOME LATE MARKET ENTRY, KLINE & CO. Healthcare Practice Manager Kathryn Greengrove Griffie predicted at a May 17 session of an Rx-to-OTC switch conference sponsored by International Business Communications in Washington, D.C. Griffie prophesied that sales of an OTC version of Glaxo Wellcome's Zantac H2-antagonist "will be significant" because "brand recognition for Zantac is huge."
Advertisement

Related Content

Rx-Strength Pepcid Could Join Prilosec OTC In Consumer Market
Rx-Strength Pepcid Could Join Prilosec OTC In Consumer Market
Rx-Strength Pepcid Could Join Prilosec OTC In Consumer Market

Topics

Advertisement
UsernamePublicRestriction

Register

PS083847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel